RespireRx Pharmaceuticals Inc. to Present at the 28th Annual Roth Conference on March 16, 2016
March 11 2016 - 8:00AM
Marketwired
RespireRx Pharmaceuticals Inc. to Present at the 28th Annual
Roth Conference on March 16, 2016
GLEN ROCK, NJ-(Marketwired - Mar 11, 2016) - RespireRx
Pharmaceuticals Inc. (OTCQB: RSPI) ("RespireRx" or the "Company"),
a leader in the development of medicines for respiratory disorders,
including sleep apneas and drug-induced respiratory depression,
announced that the Company's President and CEO, and Vice Chairman
of the Board of Directors, James S. Manuso, Ph.D., will present at
the 28th Annual Roth Conference (www.roth.com) on Wednesday, March
16, 2016 at 8:30 AM Pacific Daylight Time (11:30 AM EDT). The
Conference is sponsored by Roth Capital Partners, LLC and is being
held at The Ritz-Carlton Hotel, Dana Point, California, from March
13 through March 16, 2016.
Commented Dr. Manuso, "The Roth Conference provides an excellent
forum for updating investors on RespireRx's ongoing research and
development programs. I look forward to discussing the Company's
FDA-cleared, Phase 2A clinical trial testing the impact of the oral
ampakine, CX-1739, on opioid-induced respiratory depression." Dr.
Manuso also will also provide information on the Company's other
product pipeline candidates, including dronabinol, and the
Company's development timelines. Dr. Manuso concluded, "We are
eager to continue to update shareholders and other stakeholders on
the progress of RespireRx's scientific, clinical and regulatory
development initiatives during 2016."
Dr. Manuso's presentation and accompanying slides will be
accessible live, via webcast, at
http://wsw.com/webcast/roth30/rspi. Replays will be available one
hour after the presentation on RespireRx's website at
www.respirerx.com, by clicking on the investors tab and following
the links and instructions. A copy of the slide presentation to be
presented at the conference will be submitted in a Form 8-K filing
by the Company with the U.S. Securities and Exchange Commission
prior to the presentation and will also be available in the
investors section of the RespireRx website.
About RespireRx Pharmaceuticals Inc.
RespireRx Pharmaceuticals Inc. is a leader in the development of
medicines for respiratory disorders, with a focus on sleep apneas
and drug-induced respiratory depression. The Company holds
exclusive licenses and owns patents and patent applications for
certain families of chemical compounds that claim the chemical
structures and their use in the treatment of a variety of
disorders, as well as claims for novel uses of known drugs.
RespireRx's pharmaceutical candidates in development are derived
from two platforms, as described below.
The first platform is the class of compounds known as
cannabinoids, in particular, dronabinol. Under a license agreement
with the University of Illinois, the Company has rights to patents
claiming the use of cannabinoids for the treatment of sleep-related
breathing disorders. In a double-blind, placebo-controlled,
dose-ascending Phase 2A clinical study conducted by the Company,
dronabinol produced a statistically significant reduction in the
Apnea-Hypopnea Index, the primary therapeutic end-point, and was
observed to be safe and well-tolerated in a group of patients with
Obstructive Sleep Apnea ("OSA"). The University of Illinois and
three other centers currently are investigating dronabinol in a
potentially pivotal, six week, double-blind, placebo-controlled
Phase 2B clinical trial in 120 patients with OSA. This study, which
the University of Illinois has indicated it expects to be completed
during the second quarter of 2016, is fully funded by the National
Heart, Lung and Blood Institute of the National Institutes of
Health. The Company is not managing or funding this ongoing
clinical trial.
The second platform of medicines being developed by RespireRx is
a class of proprietary compounds known as ampakines, which act to
enhance the actions of the excitatory neurotransmitter glutamate at
AMPA glutamate receptors. Several ampakines, in both oral and
injectable form, are being developed by the Company for the
treatment of a variety of breathing disorders. In clinical studies,
select ampakines have shown preliminary efficacy in central sleep
apnea and in the control of respiratory depression produced by
opioids, without altering their analgesic effects. In animal models
of orphan disorders, such as Pomp Disease, spinal cord damage and
perinatal respiratory distress, it has been demonstrated that
certain ampakines improve breathing function. The Company's
compounds belong to a new class of ampakines that do not display
the undesirable side effects previously reported in animal models
of earlier generations.
Additional information about the Company and the matters
discussed herein can be obtained on the Company's website at
www.RespireRx.com or in the Company's filings with the U.S.
Securities and Exchange Commission at www.sec.gov.
Special Note Regarding Forward-Looking Statements: Certain
statements included or incorporated by reference in this news
release, including information as to the future financial or
operating performance of the Company and its drug development
programs, constitute forward-looking statements. The words
"believe," "expect," "anticipate," "contemplate," "target," "plan,"
"intend," "continue," "budget," "estimate," "may," "schedule" and
similar expressions identify forward-looking statements.
Forward-looking statements include, among other things, statements
regarding future plans, targets, estimates and assumptions.
Forward-looking statements are necessarily based upon a number of
estimates and assumptions that, while considered reasonable by the
Company, are inherently subject to significant business, economic
and competitive uncertainties and contingencies. Many factors could
cause the Company's actual results to differ materially from those
expressed or implied in any forward-looking statements made by, or
on behalf of, the Company. Due to these various risks and
uncertainties, actual events may differ materially from current
expectations. Investors are cautioned that forward-looking
statements are not guarantees of future performance and,
accordingly, investors are cautioned not to put undue reliance on
forward-looking statements due to the inherent uncertainty therein.
Forward-looking statements are made as of the date of this news
release and the Company disclaims any intent or obligation to
update publicly such forward-looking statements, whether as a
result of new information, future events or results or
otherwise.
Company Contact: Jeff Margolis Vice-President, Treasurer and
Secretary Telephone: (917) 834-7206 E-mail:
jmargolis@respirerx.com
RespireRx Pharmaceuticals (PK) (USOTC:RSPI)
Historical Stock Chart
From Mar 2024 to Apr 2024
RespireRx Pharmaceuticals (PK) (USOTC:RSPI)
Historical Stock Chart
From Apr 2023 to Apr 2024